Galaxy Therapeutics Completes Enrollment of Primary Cohort in Pivotal SEAL IT IDE Trial

MILPITAS, Calif., May 30, 2025 /PRNewswire/ -- Galaxy Therapeutics, a privately held, clinical-stage medical device company focused on treating brain aneurysms, today announced the completion of enrollment in the primary cohort of its SEAL IT IDE trial. The trial's primary arm, known as...

Read More